2005, Number 1
Extended-release galantamine efficacy in Alzheimer’s disease vascular or mixed dementia open trial
Albert-Meza G, Santos-Zambrano J, Mena-Barranco F, Navarrete-Báez H, Viveros-Erosa MA, Pérez-Hernández M, González-Garza J
Full text
Language: Spanish
References: 7
Page: 34-37
PDF size: 84.45 Kb.
ABSTRACT
Objective: To evaluate the efficacy and safety of galantamine in the treatment of Alzheimer’s disease or vascular or mixed dementia. Design: Open-label, multicenter trial with outpatients with mild to moderate dementia symptoms due to Alzheimer’s Disease (AD), vascular o mixed. Intervention: Patients received in a open-label fashion extended-release galantamine once a day 8, 16 or 24 mg/day, according to dose-response. Main outcome measures: Scores on the MMSE, clock-drawing task, ADAS-cog scale, the clinician’s interview based impression of change, and caregiver input (Zarit caregiver burder questionnaire), were assessesed. Methods: Extended-release galantamine was given once a day at 8, 16 y 24 mg/day. Results: Of 27 patients, 11 (41%) male, and 16 (59%) female, mean 73 ± 8 years. For efifcacy end-points showed statistically significant improvement in MMSE baseline mean 17 ± 3 vs. final 24 ± 3 (p = 0.001), ADAS-cog (decrease is improvement) baseline mean 28 ± 7 vs. 22 ± 8, p = 0.05. Clock drawing test scores baseline 4.5 vs. final 7, p = 0.01 and interpretation, cognitive impairment (baseoine 93% vs. final 18%) and without cognitive impairment baseline 7% vs. final 82% (p = 0.01 c2). Adverse events: 1 (3%) patient recorded irritability that improved with dose decrease. Conclusion: The treatment with extended release galantamine improved cognitive tasks and that improved the daily living activities and decrease the burden of the caregiver (Zarit).REFERENCES